Skip to main content
. 2022 Oct 21;13:1032411. doi: 10.3389/fimmu.2022.1032411

Table 1.

Demographic data of the study’s participants.

Groups Age Sex Days between vaccine doses Days of symptoms onset COVID-19 diagnosis
Placebo (n=8) 54 (36-64) 62,5% F
37,5% M
Vaccinees
18-59 (n=29) 36 (31-42) 55,2% F 15 (14-18)
44,8% M
≥60 (n=24) 67 (63-70) 33,3% F 16 (14-21)
66,7% M
COVID-19 cases
Hospitalized (n=8) 53 (43-62) 12,5% F 19 (17-22) 75% PCR
87,5% M 25% Serology
Non-hospitalized (n=9) 40 (33-44) 55,6% F 46 (34-65) 100% PCR
44,4% M